Talaris Therapeutics provides high-resolution analysis of HLA mismatches in a Phase 2 trial of living donor kidney transplantation

2021-12-15 00:24:09 By : Mr. Davy Qiu

Analysis confirms that FCR001 induces durable tolerance in highly mismatched related and unrelated recipients

Boston and Louisville, Kentucky, December 14, 2021 (Global News Agency) - Talaris Therapeutics, Inc. (NASDAQ: TALS), a clinical advanced cell therapy company, today New analysis of HLA mismatch between donors. Recipients participating in the company's Phase 2 trial of living donor kidney transplantation (LDKT). High-resolution allelic typing of six loci found that FCR001 induces durable immune tolerance in highly mismatched related and unrelated receptors. The American Society of Hematology (ASH) Fowler McCormick, Professor of Surgery at Northwestern University Feinberg School of Medicine, and Joseph R. Leventhal, MD, Ph.D., lead investigator of the American Society of Hematology (ASH) Phase 2 study, shared these findings in an oral report) annual meeting.

The new analysis is based on DNA samples collected in the FCR001 Phase 2 trial conducted by Talaris in living kidney transplant recipients. The focus of the analysis is to use the high-resolution allelic typing of HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 to assess the degree of donor/recipient HLA mismatches, and understand their and capabilities The correlation between the two establishes a long-lasting mosaic in this patient sample.

All 12 relevant HLA alleles were evaluated for 29 samples out of 37 donor/recipient pairs; because the samples did not have enough DNA to detect locus DPB1, the other three donor/recipient pairs were evaluated An evaluation of 10 alleles was performed. In the former group, 21 of the 29 donor/acceptor pairs had 6/12 or more mismatches; in the latter group, two of the three pairs had 5/10 or more mismatches. match. Despite this high degree of mismatch, the persistent chimerism induced by FCR001 allowed the complete discontinuation of immunosuppression (IS) in 25 of these 32 subjects, with a period of 3.5 to 11 years for discontinuation of IS. Twelve of these 25 pairs were not associated with ≥8 HLA mismatches, and most of the patients receiving treatment showed >95% donor whole blood/T cell mosaicism. As previously reported, the incidence of GvHD is limited, and there are two cases, both of which occurred in the context of female donors and unrelated male recipients. The exclusion criteria for this donor-acceptor pairing have been added to the Phase 2 trial.

"We are pleased to share this new, more detailed examination of patients with HLA mismatches in our phase 2 trial, which shows that FCR001 induces durable immune tolerance at very high levels of mismatches," said Nancy, MD. Krieger said, Talaris. "As we conduct the ongoing Phase 3 registration study in LDKT, FREEDOM-1, and as we continue to promote the application of allogeneic hematopoietic stem cell transplantation therapies to other areas where patient demand is high, these insights are very valuable ."

About Talaris Therapeutics Talaris Therapeutics, Inc. is a late-stage clinical biopharmaceutical company that develops research and disposable allogeneic cell therapies that may change solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood , Immunity and metabolic disorders. Talaris has a corporate office in Boston, Massachusetts, a cell processing facility in Louisville, Kentucky, and other research facilities in Houston, Texas.

Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended, including but not limited to Talaris Therapeutics, Inc. ("Talaris", "Company", " Our" or "our") strategy, business plan and focus; the progress and timing of the preclinical and clinical development of the Talaris project, including FCR001, and the promotion of the continued application of allogeneic hematopoietic stem cell transplantation therapy in other areas of high patient demand Extension. "May", "may", "will", "may", "should", "should", "expect", "plan", "anticipate", "intend", "believe", "expect" and other words " "Estimate", "seek", "forecast", "future", "project", "potential", "continue", "target" or the negative words and similar words or expressions of these terms are intended to identify forward-looking statements, although they are not All forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs, and are subject to many risks, uncertainties and important factors, which may cause actual events or results to be expressed or implied in any forward-looking statements. The content is quite different. The statement contained in this press release includes, but is not limited to, the risks associated with: the timing and expected time and results of its clinical trials; Talaris' clinical trial results may not be able to predict the risks of future results related to future clinical trials; the company's success The ability to prove the safety and effectiveness of its drug candidates. These and other risks and uncertainties have been updated in the section entitled “Risk Factors” in the company’s quarterly report on Form 10-Q for the quarter ended September 30, 2021, and any subsequent filings with the U.S. Securities and Exchange Commission. Detailed description. In addition, any forward-looking statements only represent the views of Talaris as of today and should not be considered as representing our views on any subsequent date. Talaris expressly disclaims any obligation to update any forward-looking statements. No representations or guarantees (express or implied) are made as to the accuracy of any such forward-looking statements.

Media Contact Lisa Raffensperger Tenbridge Communications lisa@tenbridgecommunications.com (617) 903-8783

Investor contact information Chris Brinzey ICR Westwicke chris.brinzey@westwicke.com (339) 970-2843

Both companies currently play a secondary role in front of the leaders in the coronavirus vaccine market.

After the new Covid variant appears to partially evade its Covid injection protection, is Pfizer's stock worth buying? Can PFE stocks be bought now?

A new private study by Discovery Health in South Africa shows that Pfizer's (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccines are effective against omicron variant infections 33%. However, the company reported that the variant appeared to cause a less serious disease. Based on 211,000 positive COVID-19 cases, the data shows that the risk of hospitalization is 29% lower than the first wave of infections in South Africa in mid-2020. Pfizer/BioNTech injections are 70% effective before prevention

(Bloomberg)-The World Health Organization is concerned that the omicron variant is considered mild, even though it spreads faster than any previous Covid-19 strain. Can Crypto Island Paradise Indoor Farm reach the height of a skyscraper? China is building the world's largest national park system Boris Johnson. Angry members of Congress worry that his next mistake may be fatal. Omicron now accounts for 3% of all sequencing cases in the U.S.

(Bloomberg)-New research data shows that Pfizer’s experimental Covid-19 pills are very effective in keeping patients away from the hospital, but are not very good at eliminating the milder symptoms usually associated with breakthrough infections. Most of the reading comes from Bloomberg Zero Tax, Golf, and Beach Houses. Can the indoor farm of encrypted island paradise reach the height of a skyscraper? China is building the world's largest national park system, Boris Johnson, angry members of Congress worry that his next mistake may be fatal

Pfizer said on Monday that it had agreed to acquire Arena Pharmaceuticals Inc. for approximately US$6.7 billion, making Pfizer’s share price hit a record high, and Arena’s share price had the largest single-day increase.

One of the biggest stories of the 2021 coronavirus pandemic is the huge gap between red and blue. Although the impact of the virus last year was relatively nonpartisan, Republicans and conservatives were vaccinated at a slower rate, leading to significant and increasingly serious results in the Red Zone. The campaign to vaccinate children follows the same pattern-only more obvious, and to some extent heralds fierce battles in the future.

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has awarded its INVOS™ 7100 brain/body oximetry system a 510(k) ) Permit, applicable to children from birth to age 18. The INVOS system collects key signals to inform pediatric clinicians of the time associated with hemodynamic management, ventilation and resuscitation of premature infants, neonates, children and other pediatric patients Key decision

The decision is the latest indication that the emergence of Omicron and the increase in the number of cases in certain areas of the country have complicated the return to normalcy.

Pfizer said that additional data confirmed the mid-term results. If the drug is taken within three days of the onset of symptoms, the risk of hospitalization or death can be reduced by 89%.

After Merck's Covid pill, Monoprevir, is reviewed by an FDA consultant, will it be bought or sold? Is MRK stock now bought or sold?

Keith Smith, who has been on a ventilator, received two doses of the controversial drug before his condition worsened. He died on Sunday at the age of 52.

Pfizer Inc. cheered investors on Tuesday through the final data of its late-stage COVID-19 antiviral drug trial, which found that if taken shortly after symptoms appear, it can reduce the risk of hospitalization or death in high-risk adults 89%, confirming the first set of data released last month.

Author: Dr. David Bautz Nasdaq: TNXP Read the complete TNXP research report business update multiple research centers. These facilities will enable the company to better control early

Sigilon Therapeutics Inc. will lay off 40 employees, accounting for 38% of its total workforce, and reduce its work on drugs for rare blood diseases.

A Bucks County biopharmaceutical company dedicated to the treatment of chronic hepatitis B has signed a licensing and cooperation agreement with a Chinese pharmaceutical company worth up to US$300 million. According to the terms of the agreement, Jinan Qilu Pharmaceutical will obtain the exclusive rights of Arbutus Biopharma's main new drug candidate for the treatment or prevention of hepatitis B, AB-729, in Mainland China, Hong Kong, Macau and Taiwan. In return, Warminster’s Arbutus (NASDAQ: ABUS) will receive an upfront payment of US$40 million, up to US$245 million in development and commercialization milestone payments, double-digit tiered royalties, and 15 million Equity investment in US dollars. Arbutus CEO William Collier called Qilu an "ideal partner" because the company has extensive development, regulatory and commercialization capabilities in China.

We asked doctors and dietitians to explain who needs to pay attention to high-histamine foods.

Of course, based on the CDC's study of 43 reported cases, we can do better than this title.

Pfizer stated that the pill to treat COVID-19 may be approved at the end of the year or early 2022: “It changes the rules of the game”

(Bloomberg)-Follow our live report on this breaking news here. Most of the reading comes from Bloomberg. Zero taxes, golf and beach villas create a crypto island paradise indoor farm can reach the height of a skyscraper? China is building the world’s largest national park system, Boris Johnson’s angry members of Congress worry that his next mistake may be fatal. The Covid-19 vaccines from Pfizer and BioNTech, as well as vaccines developed by Johnson & Johnson, seem to be largely Prevented serious diseases from the omicron variant South Africa